AR-C118925XX
Based on 3 publication(s) in Google Scholar
AR-C118925XX is a selective P2Y2 receptor antagonist. AR-C118925XX inhibits ATP-induced IL-6 production and phosphorylation of p38. AR-C118925XX also inhibits Bleomycin (HY-108345)-induced dermal fibrosis in mice. AR-C118925XX also inhibits ATP-induced tumor growth.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.02%
- CAS No.: 216657-60-2
- Formule: C28H23N7O3S
- Masse moléculaire:537.59
-
Stockage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cancer Compound Library
HY-L025
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Antidepressant Compound Library
HY-L108
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
MCE Bioactive Compound Library
HY-L001V
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) AR-C118925XX
More
Customer Validation & Images
-
IF
-
Cell Migration/Invasion Assay
-
Bio/Physico-chemical Assay
-
Cell Migration/Invasion Assay
-
IF
Voir tous les produits spécifiques à Isoform P2Y Receptor
More
Activité biologique
|
P2Y2 Receptor |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 216657-60-2
-
Appearance Solid
-
Masse moléculaire 537.59
-
Formule C28H23N7O3S
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC=C(CN2C=C(C3C4=CC=C(C)C=C4C=CC5=CC(C)=CC=C53)C(NC2=O)=S)O1)NC6=NN=NN6
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. [Abstract]2026 Mar 9;44(3):658-675.e12. PMID: 41687606
AR-C118925XX purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2026 Mar 9;44(3):658-675.e12. [Abstract]
Representative immunofluorescence images and quantification of LEPR+DAB2+ KCs in mouse LMs (n = 10 mice/group). Scale bars, 100 μm. AR-C118925XX (10 mg/kg; i.p.; every 2 days, beginning 2 days after chemotherapy) reduced LEPR+ KCs infiltration into metastatic lesions.
AR-C118925XX purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2026 Mar 9;44(3):658-675.e12. [Abstract]
Schematic of the transwell assay to assess LEPR+ KCs chemotaxis towards 5-FU-treated AKP cells. Percentage of LEPR+ KCs migrating from the chamber treated with AR-C118925XX (10 μmol/L; 12 h).
-
Am J Physiol Cell Physiol
2023 Nov 1;325(5):C1228-C1243. PMID: 37721000
AR-C118925XX purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2023 Nov 1;325(5):C1228-C1243. [Abstract]
Representative transmigration images and quantitative analysis of cells treated with P2Y2 blocker AR-C118925XX (100 nM; 18 h) (n = 20, scale bar = 100 µm). AR-C118925XX inhibited ATP-induced migration of CD34+ VW-SCs.
AR-C118925XX purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2023 Nov 1;325(5):C1228-C1243. [Abstract]
Representative images showing the migration and differentiation of CD34+ cells indicated by tdTomato (tdT) in matrigel plugs (scale bar = 50 μm). AR-C118925XX (100 nM; s.c.; single dose) inhibited ATP-driven CD34+ cell accumulation in Matrigel plugs and the increase in CD31+ cells colocalized with migrated CD34+ cells.
-
AR-C118925XX purchased from MedChemExpress. Usage Cited in: Res Sq. 2025 May 18.
AR-C118925XX (100 μM; 24 h) reduced H2O2 levels in primary astrocytes with reactivity induced by H2O2.
Solvant et solubilité
DMSO : 100 mg/mL (186.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (4.65 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (544 KB)
- English - EN (544 KB)
- Français - FR (544 KB)
- Deutsch - DE (544 KB)
- Norwegian - NO (544 KB)
- Español - ES (544 KB)
- Swedish - SV (544 KB)
- Italian - IT (544 KB)
- Korean - KR (544 KB)
- Portuguese - PT (544 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Perera LMB, et al. The Regulation of Skin Fibrosis in Systemic Sclerosis by Extracellular ATP via P2Y2 Purinergic Receptor. J Invest Dermatol. 2019 Apr;139(4):890-899. [Content Brief]
[2]. Dong CR, et al. AKT/GSK-3beta/VEGF signaling is involved in P2RY2 activation-induced the proliferation and metastasis of gastric cancer. Carcinogenesis. 2022 Dec 5:bgac095. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8602 mL | 9.3008 mL | 18.6015 mL | 46.5038 mL |
| 5 mM | 0.3720 mL | 1.8602 mL | 3.7203 mL | 9.3008 mL | |
| 10 mM | 0.1860 mL | 0.9301 mL | 1.8602 mL | 4.6504 mL | |
| 15 mM | 0.1240 mL | 0.6201 mL | 1.2401 mL | 3.1003 mL | |
| 20 mM | 0.0930 mL | 0.4650 mL | 0.9301 mL | 2.3252 mL | |
| 25 mM | 0.0744 mL | 0.3720 mL | 0.7441 mL | 1.8602 mL | |
| 30 mM | 0.0620 mL | 0.3100 mL | 0.6201 mL | 1.5501 mL | |
| 40 mM | 0.0465 mL | 0.2325 mL | 0.4650 mL | 1.1626 mL | |
| 50 mM | 0.0372 mL | 0.1860 mL | 0.3720 mL | 0.9301 mL | |
| 60 mM | 0.0310 mL | 0.1550 mL | 0.3100 mL | 0.7751 mL | |
| 80 mM | 0.0233 mL | 0.1163 mL | 0.2325 mL | 0.5813 mL | |
| 100 mM | 0.0186 mL | 0.0930 mL | 0.1860 mL | 0.4650 mL |
AR-C118925XX Related Classifications
HY-110126 Related Classifications
Powered by Bioz